L-3,3-二苯基丙氨酸 | 149597-92-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: L-3,3-二苯基丙氨酸
• 中文别名: L-β-二苯基丙氨酸；3,3-二苯基-L-丙氨酸；L-Beta-二苯基丙氨酸；L-BETA-二苯基丙氨酸；3-苯基-L-苯丙氨酸
• 英文名称: L-diphenylalanine
• 英文别名: L-3,3-diphenylalanine；3,3-diphenyl-L-alanine；(2S)-2-azaniumyl-3,3-diphenylpropanoate
• CAS: 149597-92-2
• 化学式: C₁₅H₁₅NO₂
• 分子量: 241.29
• InChiKey: PECGVEGMRUZOML-AWEZNQCLSA-N

物化性质

• 熔点：
  234-240 °C
• 沸点：
  389.2±30.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  T
• 安全说明：
  S45
• 危险类别码：
  R25
• WGK Germany：
  2
• 危险品运输编号：
  UN 2811
• 海关编码：
  2922499990
• 包装等级：
  Ⅲ
• 危险类别：
  6.1
• 危险标志：
  GHS06
• 危险性描述：
  H300
• 危险性防范说明：
  P264,P301 + P310
• 储存条件：
  存储温度应保持在0°C。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: L-3,3-Diphenylalanine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H300: Fatal if swallowed
P264: Wash thoroughly after handling
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
Ingredient name: L-3,3-Diphenylalanine
CAS number: 149597-92-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C15H15NO2
Molecular weight: 241.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (L-3,3-Diphenylalanine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

S-2-氨基-3,3-二苯基丙酸是一种丙氨酸衍生物。

反应信息

• 作为反应物：
  描述：

  L-3,3-二苯基丙氨酸 在 盐酸 、 palladium on activated charcoal 、 甲酸铵 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 1-((2S)-2-((N-(tert-butoxycarbonyl)-N-methyl-L-alanyl)amino)-2-cyclohexylacetyl)-L-prolyl-β-phenyl-L-phenylalanine
  参考文献：
  名称：

  [EN] BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR
  [FR] COMPOSÉS BI-FONCTIONNELS ET PROCÉDÉS D'UBIQUITINATION CIBLÉE DU RÉCEPTEUR DES ANDROGÈNES

  摘要：

  本发明涉及具有双重功能的化合物，其功能是招募内源蛋白质到E3泛素连接酶进行降解，并使用相同的方法。更具体地，本公开提供了特定的蛋白质降解靶向嵌合物（PROTAC）分子，这些分子作为调节各种多肽和其他蛋白质的靶向泛素化的调节剂，特别是缺乏LBD的AR的一个切片变体的雄激素受体，标记为AR-V7，然后通过所述化合物进行降解和/或其他方式被抑制。

  公开号：

  WO2021236695A1
• 作为产物：
  描述：

  二苯基溴甲烷 在 盐酸 、 六甲基磷酰三胺 、 lithium hydroxide 、 正丁基锂 、 四丁基溴化铵 、 silica gel 、 lithium bromide 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 10.0h， 生成 L-3,3-二苯基丙氨酸
  参考文献：
  名称：

  Design and Synthesis of Side-Chain Conformationally Restricted Phenylalanines and Their Use for Structure-Activity Studies on Tachykinin NK-1 Receptor

  摘要：

  Constrained analogues of phenylalanine have been conceptually designed for analyzing the binding pockets of Phe(7) (S-7) and Phe(8) (S-8), two aromatic residues important for the pharmacological properties of SP, i.e., L-tetrahydroisoquinoleic acid, L-diphenylalanine, L-9-fluorenylglycine (Flg), 2-indanylglycine, the diastereomers of L-1-indanylglycine (Ing) and L-1-benz[f]indanylglycine (Bfi), and the Z and E isomers of dehydrophenylalanine (Delta(z)Phe, Delta(E)Phe). Binding studies were performed with appropriate ligands and tissue preparations allowing the discrimination of the three tachykinin binding sites, NK-1, NK-2, and NK-3. The potencies of these agonists were evaluated in the guinea pig ileum bioassay. According to the binding data, we can conclude that the S-7 subsite is small, only the gauche (-) probe [(2S,3S)-Ing(7)]SP presents a high affinity for specific NK-1 binding sites. Surprisingly, the [Delta(E)Phe(7)]SP analogue, which projects the aromatic ring toward the trans orientation, is over 40-fold more potent than the Z isomer, [Delta(Z)Phe(7)]SP. A plausible explanation of these conflictual results Is that either the binding protein quenches the minor trans rotamer of [(2S,3S)-Ing(7)]SP in solution or this constrained amino acid side chain rotates when inserted in the protein. In position 8, the high binding affinities of [Flg(8)]SP and [(2S,3S)-Bfi(8)]SP suggest that the S-8 subsite is large enough to accept two aromatic rings in the gauche (-) and one aromatic ring in the trans direction. Peptides bearing two conformational probes in positions 7, 8, or 9 led to postulate that S-7, S-8, and S-9 subsites are independent from each other. The volumes available for side chains 7 and 8 can be estimated to be close to 110 and 240 Angstrom(3), respectively. The large volume of the S-8 subsite raises question on the localization of the SP-binding site in the NK-1 receptor. If SP were to bind in the transmembrane domains, the cleft defined by the seven transmembrane segments must rearrange during the binding process in order to bind a peptide in an ac-helical structure and at least one large binding subsite in position 8. Thus, indirect topographical analysis with constrained amino acids might contribute to the analysis of the receptor/ligand dynamics. Finally, this study demonstrates that a good knowledge of the peptidic backbone structure and a combination of constrained amino acids are prerequisites to confidently attribute the preferred orientation(s) of an amino acid side chain.

  DOI：

  10.1021/jm00037a009

文献信息

• [EN] NOVEL HEPCIDIN MIMETICS AND USES THEREOF<br/>[FR] NOUVEAUX MIMÉTIQUES D'HEPCIDINE ET LEURS UTILISATIONS
  申请人：BAYER HEALTHCARE LLC

  公开号：WO2018128828A1

  公开（公告）日：2018-07-12

  The present invention relates to novel peptides acting as hepcidin mimetics, as well as analogues and derivatives thereof. The invention further relates to compositions comprising the peptides of the present invention, and to the use of the peptides in the prophylaxis and treatment of hepcidin-associated disorders, including prophylaxis and treatment of iron overload diseases such as hemochromatosis, iron-loading anemias such as thalassemia, and diseases being associated with ineffective or augmented erythropoiesis, as well as further related conditions and disorders described herein.

  本发明涉及作为赫普西定类似物的新型肽，以及其类似物和衍生物。该发明还涉及包含本发明肽的组合物，以及在预防和治疗赫普西定相关疾病中使用这些肽，包括预防和治疗铁过载疾病如血色病、铁负荷性贫血如地中海贫血，以及与效率低下或增强的红细胞生成相关的疾病，以及本文所述的进一步相关病症和疾病。
• New Chiral Derivatizing Agents: Convenient Determination of Absolute Configurations of Free Amino Acids by ¹H NMR
  作者：Michio Kurosu、Kai Li

  DOI：10.1021/ol8028719

  日期：2009.2.19

  The chiral carbonate reagents 5 allow for the direct and unambiguous determination of the absolute configurations of a wide range of free amino acids using 1H NMR. By using a ∼3:1 mixture of (S)-5 and (R)-5, absolute configurations of the corresponding carbamates are determined by only analyzing the nitrogen protons.

  手性碳酸酯试剂5允许使用1 H NMR直接和明确地确定各种游离氨基酸的绝对构型。通过使用〜（S）-5和（R）-5的〜3：1混合物，仅通过分析氮质子即可确定相应氨基甲酸酯的绝对构型。
• [EN] AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS CD36 À BASE D'AZASULFURYLPEPTIDES ET UTILISATIONS DE CEUX-CI
  申请人：RSEM LTD PARTNERSHIP

  公开号：WO2016029324A1

  公开（公告）日：2016-03-03

  Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-mediated inflammatory disease, disorder or condition, and methods of obtaining such azasulfuryl-containing peptidomimetics, are also disclosed.

  揭示了能够抑制CD36活性的新型含氮硫酰基的肽类模拟物。还揭示了利用这些含氮硫酰基的肽类模拟物治疗与CD36相关的疾病、紊乱或状况，包括TLR2介导的炎症性疾病、紊乱或状况的用途，以及获取这种含氮硫酰基的肽类模拟物的方法。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。
• Ligand‐Enabled Catalytic CH Arylation of Aliphatic Amines by a Four‐Membered‐Ring Cyclopalladation Pathway
  作者：Chuan He、Matthew J. Gaunt

  DOI：10.1002/anie.201508912

  日期：2015.12.21

  palladium‐catalyzed CH arylation of aliphatic amines with arylboronic esters is described, proceeding through a four‐membered‐ring cyclopalladation pathway. Crucial to the successful outcome of this reaction is the action of an amino‐acid‐derived ligand. A range of hindered secondary amines and arylboronic esters are compatible with this process and the products of the arylation can be advanced to

  描述了钯催化的脂肪族胺与芳基硼酸酯的CH芳基化，并通过四元环环钯途径进行。该反应成功的关键是氨基酸衍生的配体的作用。一系列受阻的仲胺和芳基硼酸酯与该方法相容，并且芳基化的产物可以通过连续的CH活化反应推进为复杂的多环分子。